Saturday, October 16, 2021
Mitochondrial Health

Inhibikase Therapeutics, Inc @ Sachs NIF

Milton Werner, CEO of @Inhibikase, provided an update on the Company’s development of IkT-148009 for the treatment of #Parkinsons disease and clinical measures of dosing pharmacokinetics at the 4th Annual Neuroscience Innovation Forum for Business Development, Licensing and Investment, hosted by Sachs Associates


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *